D715B6Z
Brachytherapy Lymphatics, Thorax to None with Cesium 131 (Cs-131), Low Dose Rate (LDR) Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | D Radiation Therapy |
| Body System | 7 Lymphatic and Hematologic System |
| Operation | 1 Brachytherapy |
| Body Part | 5 Lymphatics, Thorax |
| Approach | B Low Dose Rate (LDR) |
| Device | 6 Cesium 131 (Cs-131) |
| Qualifier | Z None |
Procedure Overview
Brachytherapy of the lymphatic and hematologic system involves placing a radioactive source directly into or adjacent to lymphatic tissue, delivering a concentrated, localized dose while sparing tissue farther from the source. This is less common than external beam treatment for this body system but may be used for localized nodal disease where direct source placement offers better dose control, or in combination with surgery for residual microscopic tumor at a nodal bed.
The radioactive material can be left in place temporarily and removed after a calculated dose is delivered, or in some cases placed permanently as small seeds that decay over time. The approach is chosen when the anatomic target allows safe, direct access for source placement.
Anatomy & Axis Detail
Lymphatics, Thorax
Mediastinal nodal stations such as the paratracheal, subcarinal, and hilar groups drain the lungs and are frequent sites of nodal spread from lung cancer, esophageal cancer, or recurrent lymphoma. Brachytherapy here places sealed radioactive sources directly into or against involved nodal tissue, often via catheters positioned intraoperatively after resection to treat a nodal bed or bronchial stump where residual disease is suspected. This delivers a concentrated boost while limiting exposure to the heart, great vessels, esophagus, and spinal cord that crowd the mediastinum. Because these nodes sit deep among vital structures, careful catheter placement and source dwell planning are essential, and documentation should specify the approach used and whether treatment followed surgical exploration.
Modality Qualifier: Low Dose Rate (LDR)
Low Dose Rate (LDR) denotes brachytherapy using a source of lower activity that remains implanted or applied over an extended period, from many hours to a few days, exploiting continuous low-level irradiation for tumor control. This differs from High Dose Rate (HDR), which compresses the same general goal into brief, higher-intensity sessions, and LDR is often chosen for permanent seed implants such as certain prostate treatments.
Isotope: Cesium 131 (Cs-131)
Cesium-131 is a permanent-seed brachytherapy isotope, similar in application to I-125 and Pd-103, implanted for prostate and other solid tumors, but distinguished by its notably shorter half-life of roughly 9.7 days. This compresses dose delivery into a shorter window than either I-125 or Pd-103, which can be clinically relevant for tumor kinetics and post-implant management.
Coding & Documentation
Coders confirm brachytherapy by finding documentation of a radioactive source being implanted, inserted, or applied directly at or near the lymphatic target, along with whether the source was temporary or permanent, which determines the correct approach and qualifier values. The radiation oncology or interventional procedure note should specify the isotope, source configuration, and duration of placement.
A frequent mistake is confusing a temporary applicator left in place for a planned removal with a permanent seed implant, which changes both the qualifier and the expected follow-up documentation. Coders should also verify the treated body part matches the nodal region named in the operative note rather than assuming it based on the underlying diagnosis.